Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$11,593,048
-$1,381,995 QoQ
Shares Held
73,973
-12.9% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#158
of 1,602 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026MANNING & NAPIER ADVISORS LLC holds $150,564,627 across 15 Drug Manufacturers - General names. NVS ranks #6 (7.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SNY |
Sanofi
|
1,222,650 | $52,158,249 | |
| 2 | MRK |
Merck & Co., Inc.
|
173,781 | $22,330,858 | |
| 3 | ABBV |
AbbVie Inc.
|
85,352 | $21,477,977 | |
| 4 | GSK |
GSK plc
|
277,309 | $14,536,537 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
102,792 | $12,986,741 | |
| 6 | NVS |
Novartis AG
This page
|
73,973 | $11,593,048 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
184,742 | $10,644,834 | |
| 8 | JNJ |
Johnson & Johnson
|
9,373 | $2,380,460 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,593,048 | 73,973 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $12,975,043 | 84,943 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $11,836,415 | 85,852 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $11,346,418 | 88,478 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $11,606,674 | 95,915 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $14,861,175 | 133,308 | Shares | Sole | 2025-04-22 | |
| 2024-12-31 | $13,321,544 | 136,898 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $16,305,580 | 141,763 | Shares | Sole | 2024-10-17 | |
| 2024-06-30 | $15,044,288 | 141,314 | Shares | Sole | 2024-07-11 | |
| No filing history on record for this holder in this stock. | ||||||